News & Updates
Filter by Specialty:
Cardiorenal benefit with investigational GLP-1 RA independent of concurrent SGLT2 inhibitor
The glucagon-like peptide-1 receptor agonist (GLP-1 RA) efpeglenatide affords cardiovascular and renal protection that is not explained by concurrent use of a sodium-glucose co-transporter-2 (SGLT2) inhibitor in patients with type 2 diabetes (T2D), according to an exploratory analysis of AMPLITUDE-O.
Cardiorenal benefit with investigational GLP-1 RA independent of concurrent SGLT2 inhibitor
30 Nov 2021
Repurposing a broad-spectrum antiviral drug may help treat asymptomatic, mild COVID-19
The oral antiviral drug umifenovir, which is used to treat influenza, appears to be beneficial in COVID-19 patients who are asymptomatic or with mild symptoms, with a phase III study showing that the drug is well tolerated and can induce viral clearance within 5 days.
Repurposing a broad-spectrum antiviral drug may help treat asymptomatic, mild COVID-19
29 Nov 2021
Add-on ezetimibe helps reduce LDL-C in post-ACS patients
The addition of ezetimibe to a statin led to reductions in low-density lipoprotein-cholesterol (LDL-C) in patients who have been stabilized after the presentation of an acute coronary syndrome (ACS), according to data presented at AHA 2021.
